Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06820723 · ClinicalTrials.gov registry record · Phase 2
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
A Phase 2 study, sponsored by Ohio State University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT06820723 is a Phase 2 study that has not yet begun recruiting, run by Ohio State University. The registered enrollment target is 40 participants.
The verdict
NCT06820723, a Phase 2 study, has not yet begun recruiting, sponsored by Ohio State University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.
Interventions
- DRUG Placebo
- DRUG CYB003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-11 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06820723
The ClinicalTrials.gov registry entry for NCT06820723 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06820723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06820723 about?
NCT06820723 is a clinical study titled "A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety". The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self...
What is the current status of trial NCT06820723?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-11. Estimated completion is 2027-11.
What interventions are being tested in trial NCT06820723?
The interventions under investigation include: Placebo (DRUG), CYB003 (DRUG).
Who is sponsoring clinical trial NCT06820723?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.